CA
TMO icon

Crumly & Associates’s Thermo Fisher Scientific TMO Stock Holding History

Crumly & Associates’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-540
Closed -$273K – 134
2023
Q3 		$273K Sell
540
-383
-41% -$204K 0.11% 100
2023
Q2 		$481K Sell
923
-351
-28% -$189K 0.19% 75
2023
Q1 		$734K Buy
1,274
+19
+2% +$10.7K 0.32% 54
2022
Q4 		$691K Sell
1,255
-17
-1% -$9.01K 0.26% 47
2022
Q3 		$645K Buy
1,272
+9
+0.7% +$5.04K 0.27% 47
2022
Q2 		$686K Buy
1,263
+81
+7% +$44.6K 0.29% 50
2022
Q1 		$698K Buy
1,182
+13
+1% +$7.47K 0.26% 60
2021
Q4 		$695K Buy
1,169
+70
+6% +$43.7K 0.27% 57
2021
Q3 		$628K Buy
1,099
+54
+5% +$29.6K 0.29% 58
2021
Q2 		$527K Buy
1,045
+168
+19% +$79.3K 0.26% 65
2021
Q1 		$400K Buy
877
+359
+69% +$171K 0.23% 57
2020
Q4 		$267K Buy
+518
New +$243K 0.19% 60

Other funds holding TMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Crumly & Associates's TMO Position: Q4 2023 in Review

Crumly & Associates sold out of Thermo Fisher Scientific (TMO) in Q4 2023, closing a stake of 540 shares — an estimated $273K sold.

Crumly & Associates first reported a position in TMO in Q4 2020 and held it in 12 quarters. The position peaked at $734K in Q1 2023. 2,487 funds tracked by Wall St. Rank hold TMO as of Q4 2023.

  • Crumly & Associates reported no remaining Thermo Fisher Scientific position as of Q4 2023 after selling out during the quarter.
  • Crumly & Associates sold 540 Thermo Fisher Scientific shares in Q4 2023, an estimated $273K.
  • Crumly & Associates first reported a position in Thermo Fisher Scientific in Q4 2020 and held it in 12 quarters.
  • Crumly & Associates's Thermo Fisher Scientific position peaked at $734K in Q1 2023.
  • 2,487 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q4 2023.

Based on Crumly & Associates's 13F filing for Q4 2023, filed 29 Jan 2024.